KLRA (Kailera Therapeutics) Operating Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Operating Margin %?

Kailera Therapeutics KLRA +2.24% 11 Operating Margin % is 0.00% as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Kailera Therapeutics ranks worse than 106157.01% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Kailera Therapeutics's Operating Income for the six months ended in Dec. 2025 was $-158.34 Mil. Kailera Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Kailera Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Kailera Therapeutics's Operating Margin % or its related term are showing as below:


KLRA's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.855
* Ranked among companies with meaningful Operating Margin % only.

Kailera Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Kailera Therapeutics's Operating Income for the six months ended in Dec. 2025 was $-158.34 Mil.


Kailera Therapeutics  (NAS:KLRA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Kailera Therapeutics Operating Margin % Related Terms


Kailera Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Operating Margin % Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Operating Margin %
0.00 0.00

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
Operating Margin % 0.00 0.00

KLRA vs VCEL, NUVB, IOVA: Operating Margin % Comparison

For the Biotechnology subindustry, Kailera Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kailera Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Kailera Therapeutics's Operating Margin % falls into.


KLRA
11GF Score
Kailera Therapeutics Inc KLRA
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Kailera Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-158.34 / 0
= %

Kailera Therapeutics's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-158.34 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Kailera Therapeutics (KLRA) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Kailera Therapeutics and its competitors. According to the industry distribution chart, Kailera Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry.
Is Kailera Therapeutics' Operating Margin % too high?
Kailera Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Kailera Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Operating Margin % compare to VCEL and NUVB?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #999999 out of 942 companies for Operating Margin %. This places Kailera Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price